leflunomide has been researched along with Metabolic Syndrome in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 5.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 1.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costa, NT | 1 |
| Scavuzzi, BM | 1 |
| Iriyoda, TMV | 1 |
| Lozovoy, MAB | 1 |
| Alfieri, DF | 1 |
| de Medeiros, FA | 1 |
| de Sá, MC | 1 |
| Micheletti, PL | 1 |
| Sekiguchi, BA | 1 |
| Reiche, EMV | 1 |
| Maes, M | 1 |
| Simão, ANC | 1 |
| Dichi, I | 1 |
1 other study available for leflunomide and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Advanced Oxidation Protein Products; Aged; Antirheumatic Agents; Arthritis, Rheum | 2018 |